Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Non-Current Assets data on file, last reported at $243.3 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $243.3 million, down 38.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $892.0 million (down 56.74% YoY), and the FY2025 annual result was $244.2 million, down 52.09% from the prior year.
• Non-Current Assets held at $243.3 million in Q1 2026 per DNLI's latest filing, from $244.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $607.5 million in Q1 2024 and troughed at $81.7 million in Q2 2023.
• A 5-year average of $270.5 million and a median of $231.5 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets slumped 82.66% in 2022, then jumped 621.67% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $87.9 million in 2022, then gained by 2.11% to $89.8 million in 2023, then jumped by 467.77% to $509.7 million in 2024, then plunged by 52.09% to $244.2 million in 2025, then fell by 0.38% to $243.3 million in 2026.
• Business Quant data shows DNLI's Non-Current Assets at $243.3 million in Q1 2026, $244.2 million in Q4 2025, and $173.0 million in Q3 2025.